Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Praful Ravi, MB, BChir, MRCP
Advertisement
Articles by Praful Ravi, MB, BChir, MRCP
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png?w=350&fit=crop&auto=format)
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Praful Ravi, MB, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
Advertisement
Latest Updated Articles
177Lu-PSMA-617 Trial May Be Efficacious in Advanced PSMA-Expressing ccRCCPublished: July 25th 2025 | Updated:
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png?w=300&fit=crop&auto=format)
Breaking Down the Phase 2 LASER trial of 177Lu-PSMA-617 in Clear Cell RCCPublished: July 26th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
